Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sanofi offers $18.5 billion for Genzyme

genzsano.png By Julianne Pepitone, staff reporter


NEW YORK (CNNMoney.com) -- French pharmaceutical firm Sanofi-Aventis is stepping up the pressure on U.S. biotech firm Genzyme, going public with an $18.5 billion cash offer and hinting it may consider a hostile takeover if Genzyme refuses to talk.

Sanofi said it first made the offer July 29 but decided to go public after being rebuffed by Genzyme. Monday's announcement is aimed at getting Genzyme to the table, or at the very least, to bring the offer to shareholders, said Sanofi in a statement.

"We feel we are left with no choice but to take our compelling proposal directly to your shareholders by making its terms public," Sanofi chief executive Christopher Viehbacher said in a letter sent to Genzyme.

Genzyme rebuffed the offer. "It provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board," chief executive Henri Termeer said in a response letter to Sanofi.

Sanofi's letter detailed a months-long attempt to engage Genzyme in acquisition discussions. Genzyme, a bio-pharmaceutical company that makes products to help treat rare diseases and cancer, was apparently "unwilling even to meet" said Sanofi.

Sanofi first sent Cambridge, Mass.-based Genzyme a letter on July 29 offering to buy it for $69 per share in cash. That was a 38% premium over Genzyme's closing price on July 1.

Sanofi said Genzyme also rejected an Aug. 11 proposal as well without agreeing to a meeting.

"After our repeated requests, you agreed only to let our respective financial advisors hold a meeting of limited scope," Sanofi said.

Termeer reiterated the company's previous position, saying, "without exception, each member of the Genzyme board believes this is not the right time to sell the company ... your opportunistic takeover proposal does not begin to recognize the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline."

Sanofi, which makes vaccines and drugs, said it could help Genzyme reach across the globe. But it also alluded to the smaller company's ongoing problems. Genzyme was forced to close its manufacturing plant last year because of a viral contamination, and the company recently said it could take three to four years to resolve the issue fully.

"Your continued refusal to enter into constructive discussions will serve only to further delay the ability of your shareholders to receive the substantial value [of] our offer," the Sanofi letter warned.

Neither company was available for immediate comment.

In U.S. trading, shares of Sanofi (SNY) closed down 1% while Genzyme (GENZ, Fortune 500) gained 3.4%. To top of page

Index Last Change % Change
Dow 16,058.35 -469.68 -2.84%
Nasdaq 4,636.11 -140.40 -2.94%
S&P 500 1,913.85 -58.33 -2.96%
Treasuries 2.17 -0.03 -1.27%
Data as of 10:38pm ET
Company Price Change % Change
Bank of America Corp... 15.58 -0.76 -4.65%
Apple Inc 107.72 -5.04 -4.47%
General Electric Co 23.88 -0.94 -3.79%
Ford Motor Co 13.72 -0.15 -1.08%
Microsoft Corp 41.82 -1.70 -3.91%
Data as of 4:03pm ET
Sponsors

Sections

McDonald's has been testing an all-day breakfast menu in several markets for months. Now it has said when the change will go nationwide: October 6. More

Iran could be pumping more than four million barrels of oil a day by the end of 2016, the country's oil minister tells CNN in an exclusive interview. More

How do you run a successful crowdfunding campaign? Indiegogo's CEO Slava Rubin offers his top tips and mistakes to avoid. More

Here's what you need to earn to afford a home in the 27 biggest metro areas in the country, according to HSH.com. More